arrow
K

Katsuhiko Naoki

kitasato university
H指数:39
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical outcomes and genomic features of uncommon EGFR exon 19 deletion subtypes in osimertinib-treated non-small cell lung cancer

奥希替尼治疗非小细胞肺癌中少见EGFR外显子19缺失亚型的临床结局与基因组特征

2026-08-310
PRE
Disease Kinetics and Practice Patterns in ≥4-Year Long-Term Beneficiaries of Immune Checkpoint Inhibitors for Advanced Non-small Cell Lung Cancer

晚期非小细胞肺癌免疫检查点抑制剂≥4年长期受益者的疾病动力学与实践模式

2026-07-280
PRE
Clinical Outcomes of Later-Generation EGFR-TKIs for Uncommon EGFR Mutations in NSCLC: A Multicenter Real-World Study

晚期egfr-tkis治疗NSCLC罕见EGFR突变的临床结局: 一项多中心真实世界研究

2025-10-260
OAAI
Final overall survival analysis of JCOG1205/1206: Phase III study of irinotecan/cisplatin (IP) versus etoposide/cisplatin (EP) for completely resected high-grade neuroendocrine carcinoma (HGNEC) of the lung

JCOG1205/1206研究的最终总生存分析:完全切除的肺高分化神经内分泌癌(HGNEC)中伊立替康/顺铂(IP)对比依托泊苷/顺铂(EP)的III期研究

2024-09-010
PRE
Efficacy of cemiplimab as monotherapy or in combination with chemotherapy in Japanese patients with advanced non-small cell lung cancer (aNSCLC)

西米普利单抗作为单药治疗或与化疗联合治疗日本晚期非小细胞肺癌(aNSCLC)患者的疗效

2024-09-010
PRE
Multicenter Pharmacokinetic and Pharmacodynamic Study of Pembrolizumab for Non-small-Cell Lung Cancer in Patients Aged 75 Years and Older
2024-06-173
OAAI
Promotive clinical effects of pembrolizumab with necitumumab in patients having advanced non-small cell lung cancer with PD-L1 expression of 50% or higher in a phase II study (K-TAIL-202)
2024-04-050
PRE
A Phase Study of Ubenimex Combined With Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non-Small-Cell Lung Cancer: TORG2241 (UBE-Q)
2024-01-011
OAAI
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer (vol 129, 2034, 2023)
2023-11-031
OA
Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer
2023-09-208
OA
Efficacy and safety of single-dose ivermectin in mild-to-moderate COVID-19: the double-blind, randomized, placebo-controlled CORVETTE-01 trial
2023-05-223
OAAI
Upregulation of FGF9 in Lung Adenocarcinoma Transdifferentiation to Small Cell Lung Cancer
2021-06-0320
OA
Trends of concerns from diagnosis in patients with advanced lung cancer and their family caregivers: A 2-year longitudinal study

晚期肺癌患者及其家庭照顾者的诊断关注趋势: 一项为期2年的纵向研究

2021-03-2411
OAAI